EBYHStrainsforpains, Inc.
The schedule
- Thu15Oct
EBYH must address its $1.95M debt overhang against negligible cash. A structured lifeline could price shares at $0.18, whereas toxic floorless dilution would compress the valuation to $0.10.
- Thu12Nov
Scheduled Q3 2026 public earnings release. Focus will be entirely on balance sheet survival rather than operating metrics. A credible pivot plan could lift shares to $0.14, while total operational stall drops them to $0.07.
- Thu18Feb
Given the distressed operations, EBYH is a prime candidate for a reverse merger. An LOI with a private entity would re-rate the shell to $0.15, while bankruptcy proceedings would result in $0.04.
- Tue30Mar
Year-end reporting for fiscal 2026. A clean 10-K incorporating a new strategic direction aims for $0.18, whereas unresolved audit issues would crater the stock back to $0.09.
Past
- Tue15Sep
Market expects an update on EBYH's delinquent financials, as the last reported period was Q4 2025. Resolution could stabilize the stock at $0.23, but continued delays risk pushing shares down to $0.16.
